Factors Governing the Binding and Recognition of Foreign and Self-Peptides by Mhc Class II

References

• Nepom GT, Erlich H. MHC class-II molecules and autoimmunity. Ann Rev Immunol 1991; 9: 493–525
   PubMed Web of Science ®Google Scholar
• Babbitt BP, Matsueda G, Haber E, Unanue ER, Allen PM. Antigenic competition at the level of peptide-Ia binding. Proc Natl A cad Sci 1986; 83: 4509–4513
   PubMed Web of Science ®Google Scholar
• Wraith DC, Smilek DE, Mitchell DJ, Steinman L, McDevitt HO. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell 1989; 59: 247–255
   PubMed Web of Science ®Google Scholar
• Adorini L, Sette A, Buus S, Grey HM, Darsley M, Lehmann PV, Doria G, Nagy ZA, Appella E. Interaction of an immunodominant epitope with la molecules in T cell activation. Proc Natl A cad Sci 1988; 85: 5181–5185
   Google Scholar
• Lamont AD, Powell MF, Colón SM, Miles C, Grey HM, Sette A. The use of peptide analogs with improved stability and MHC binding capacity to inhibit antigen presentation in vitro and in vivo. J Immunol 1990; 144: 2493–2498
   PubMed Web of Science ®Google Scholar
• Muller S, Adorini L, Juretic A, Nagy ZA. Selective in vivo inhibition of T cell activation by class II MHC-binding peptides administered in soluble form. J Immunol 1990; 145: 4006–4011
   Google Scholar
• Gaur A, Wiers B, Liu A, Rothbard J, Fathman CG. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 1992; 258: 1491–1494
   PubMed Web of Science ®Google Scholar
• Lamont AG, Sette A, Fujinami R, Colón SM, Miles C, Grey HM. Inhibition of experimental autoimmune encephalomyelitis induction in SJL/J mice by using a peptide with high affinity for IAS molecules. J Immunol 1990; 145: 1687–1693
   PubMed Web of Science ®Google Scholar
• Busch R, Strang G, Howland K, Rothbard JB. Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces. Int Immunol 1990; 2: 443
   Google Scholar
• Bjorkman P, Saper M, Samraoui B, Bennett W, Strominger J, Wiley D. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987; 329: 506
   PubMed Web of Science ®Google Scholar
• Fremont DH, Matsumura M, Stura EA, Peterson PA, Wilson IA. Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. Science 1992; 257: 919–927
   PubMed Web of Science ®Google Scholar
• Brown JH, Jardetsky TS, Gorga JC, Stern LJ, Urban RJ, Strominger JL, Wiley DC. Three-dimensional structure of the human class II histocompatibility antigen, HLA-DRI. Nature 1993; 364: 33–39
   PubMed Web of Science ®Google Scholar
• Zhang W, Young AC, Imarai M. Nathenson SG, Sacchettini JC. Crystal structure of the major histocompatibility complex class I H-2Kb molecule containing a single viral peptide: implications for peptide binding and T-cell receptor recognition. Proc Natl A cad Sci 1992; 89: 8403–8407
   Google Scholar
• Van Bleek GM, Nathenson SG. Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. Nature 1990; 348: 213–216
   PubMed Web of Science ®Google Scholar
• Rötzschke O, Falk K, Deres K, Schild H, Norda M, Metzger J, Jung G, Rammensee H-G. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 1990; 348: 252–254
   PubMed Web of Science ®Google Scholar
• Rudensky AY, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA., Jr. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991; 353: 622–627
   PubMed Web of Science ®Google Scholar
• Chicz RM, Urban RG, Lane WS, Ghorga JC, Stern LJ, Vignali DAA, Strominger JL. Predominant naturally processed peptides bound to HLA-DRI are derived from MHC-related molecules and are heterogenous in size. Nature 1992; 358: 764–768
   PubMed Web of Science ®Google Scholar
• Krieger JI, Karr RW, Grey HM, Yu W-Y, O'Sullivan D, Batovsky L, Zheng Z-L, Colon SM, Gaeta FCA, Sidney J, Albertson M, del Guercio M-F, Chesnut RW, Sette A. Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition. J Immunol 1991; 146: 2331–2340
   PubMed Web of Science ®Google Scholar
• Rothbard JB, Gefter ML. Interactions between immunogenic peptides and MHC protejns. Ann Rev Immunol 1991; 9: 527–565
   PubMed Web of Science ®Google Scholar
• Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to huma MHC class I and promiscuous recognition by T cells. Eur. J. Immunol. 1989; 39: 2237–2242
   Google Scholar
• O'Sullivan D, Sidney J, Appella E, Walker L, Phillips L, Colón SM, Miles C, Chesnut RW, Sette A. Characterization of the specificity of peptide binding to four DR haplotypes. J Immunol 1990; 145: 1799–1808
   PubMedGoogle Scholar
• O'Sullivan D, Arrhenius T, Sidney J, Del Guercio M-F, Albertson M, Wall M, Oseroff C, Southwood S, Colón SM, Gaeta FCA, Sette A. On the interaction of promiscuous antigenic peptides with different DR alleles. J Immunol 1991; 147: 2663–2669
   PubMed Web of Science ®Google Scholar
• Geluk A, Bloemhoff W, De Vries R. R.P., Ottenhoff T. H.M. Binding of a major T cell epitope of mycobacteria to a specific pocket within HLA-DRwl7(DR3) molecules. Eur J Immunol 1992; 22: 107–113
   PubMed Web of Science ®Google Scholar
• Rothbard JB, Busch R, Howland K, Bal V, Fenton C, Taylor WR, Lamb JR. Structural analysis of a peptide - HLA class II complex: identification of critical interactions for its formation and recognition by T cell receptor. Int Immunol 1989; 1: 479–486
   PubMedGoogle Scholar
• Hill CM, Hayball JD, Allison AA, Rothbard JB. Conformational and structural characteristics of peptides binding to HLA-DR molecules. J Immunol 1991; 147: 189–197
   Google Scholar
• Rothbard JB, Lechler RI, Howland K, Bal V, Eckels DD, Sekaly R, Long EO, Taylor WR, Lamb JR. Structural model of HLA-DRI restricted T cell antigen recognition. Cell 1988; 52: 515–527
   PubMed Web of Science ®Google Scholar
• Sette A, Buus S, Appella E, Smith JA, Chesnut R, Miles C, Colon SM, Grey HM. Prediction of MHC-binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci 1989; 86: 3296–3300
   PubMed Web of Science ®Google Scholar
• Sidney J, Oseroff C, Southwood S, Wall M, Ishioka G, Koning F, Sette A. DRB1*0301; molecules recognize a structural motif distinct from the one recognized by most DRβ1, alleles. J Immunol 1992; 149: 2634–2640
   Google Scholar
• Hammer J, Takacs B, Sinigaglia F. Identification of a motif for HLA-DRI binding peptides using M13 display libraries. J Exp Med 1992; 176(4)1007–1013
   Google Scholar
• Doolittle RF., Orfs. A primer on how to analyze derived amino acid sequence. University Science Books, Mill Valley 1986
   Google Scholar
• DeLisi C, Berzofsky JA. T cell antigenic sites tend to be amphipatic structures. Proc Natl Acad Sci 1985; 82: 7048–7052
   PubMed Web of Science ®Google Scholar
• Rothbard JB, Taylor WR. A sequence pattern common to T cell epitopes. EMBO J 1988; 7: 93–100
   PubMed Web of Science ®Google Scholar
• Dornmair K, McConnell HM. Refolding and reassembly of separate α and β chains of class II molecules of the major histocompatibility complex leads to increased peptide-binding capacity. Proc Natl Acad Sci 1990; 87: 4134–4138
   Google Scholar
• Pious D, Dixon L, Levine F, Cotner T, Johnson R. HLA class II regulation and structure. Analysis with HLA-DR3 and HLA-DP point mutants. J Exp Med 1985; 162: 1193–1207
   PubMedGoogle Scholar
• Merlins E, Smith L, Arp B, Cotner T, Celis E, Pious D. Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes. Nature 1990; 343: 71–74
   Google Scholar
• Gedde-Dahl T, Eriksen JA, Thorsby E, Gaudernack G. T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides. Hum Immunol 1992; 33: 266–274
   Google Scholar
• Quayle AJ, Wilson KB, SG LI, Kjeldsen KJ, Oftung F, Shinnick T, Sioud M, Foore O, Capra JD, Natvig JB. Peptide recognition, T cell receptor usage and HLA restriction elements of human heat-shock protein (hsp) 60 and mycobacterial 65-kDa hsp-reactive T cell clones from rheumatoid synovial fluid. Eur J Immunol 1992; 22: 1315–1322
   PubMed Web of Science ®Google Scholar
• Callahan KM, Fort MM, Obah EA, Reinherz EL, Siliciano RF. Genetic variability in HIV-1 gpl20 affects interactions with HLA molecules and T cell receptor. J Immunol 1990; 144: 3341–3346
   Google Scholar
• Yan T, Burkhardt H, Ritter T, Broker B, Mann KH, Bertling WM, von der Mark K, Emmrich F. Specificity and T cell receptor beta chain usage of a human collagen type II-reactive T cell clone derived from a healthy individual. Eur J Immunol 1992; 22: 51–56
   PubMed Web of Science ®Google Scholar
• Wiert EJHJ, vanGaans-van den Brink JAM, Gausepohl H, Prochnicka-Chalufour A, Hoogerhout P, Poolman JT. Identification of T cell epitopes occurring in a meningococcal class I outer membrane protein using overlapping peptides assembled with simultaneous multiple peptide synthesis. J Exp Med 1992; 176: 79–88
   Google Scholar
• Shanafelt M-C, Anzola J, Soderberg C, Yssel H, Turck CW, Peltz G. Epitopes on the outer surface protein a of Borrelia burgdorferi recognized by antibodies and T cells of patients with lyme disease. J Immunol 1992; 148: 218–224
   Google Scholar
• Fern J, Good MF. Promiscuous malaria peptide epitope stimulates CD45Ra T cells from peripheral blood of non-exposed donors. J Immunol 1991; 148: 907–913
   Google Scholar
• Dayan CM, Londei M, Corcoran AE, Grubeck-Loebenstein B, James RFL, Rapoport B, Feldmann M. Autoantigen recognition by thyroid-infiltrating T cells in Graves disease. Proc Natl A cad Sci 1991; 88: 7415–7419
   PubMed Web of Science ®Google Scholar
• Kuijpers KC, van Kemenade FJ, Hooibrink B, Neefjes JJ, Lucas CJ, van Lier RAW, Miedema F. HLA class I and II molecules present influenza virus antigens with different kinetics. Eur. J. Immunol. 1992; 22: 2339–2345
   Google Scholar
• Higgins JA, Lamb JR, Marsh SG, Tonks S, Hayball JD, Rosen-Bronson S, Bodmer JG, O'Hehir RE. Peptide-induced nonresponsiveness of HLA-DP restricted human T cells reactive with Dermatophagoides spp. (house dust mite). J Allergy Clin Immunol 1992; 90: 749–756
   PubMed Web of Science ®Google Scholar
• deKoster HS, Anderson DC, Termijtelen A. T cells sensitized to synthetic HLA-DR3 peptide give evidence of continuous presentation of denatured HLA-DR3 molecules by HLA-DP. J Exp Med 1989; 169: 1191–1196
   Google Scholar
• Hill Gaston JS, Life PF, van der Zee R, Jenner PJ, Colston MJ, Tonks S, Bacon PA. Epitope specificity and MHC restriction of rheumatoid arthritis synovial T cell clones which recognize a mycobacterial 65 kD a heat shock protein. Int Immunol 1991; 3: 965–972
   Google Scholar
• Ong B, Willcox N, Wordsworth P, Beeson D, Vincent A, Altmann D, Lanchbury JS, Harcourt GC, Bell JI, Newsom DJ. Critical role for the Val/Gly86 HLA-DR beta dimorphism in autoantigen presentation to human T cells. Proc Natl Acad Sci 1991; 88: 7343–7347
   PubMed Web of Science ®Google Scholar
• Naquet P, Ellis J, Tibensky D, Kenshole A, Singh B, Hodges R, Delovitch TL. T cell autoreactivity to insulin in diabetic and related non-diabetic individuals. J Immunol 1988; 140: 2569–2578
   PubMedGoogle Scholar
• Ota K., Matsui M, Milford EL, Mackin GA, Weiner HL, Hailer DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990; 346: 183–187
   PubMed Web of Science ®Google Scholar
• Martin R, Jaraquemade D, Flerlage M, Richert J, Whitaker J, Long ER, McFarlin DE, McFarland HF. Fine specificity and HLA restriction of myelin basic protein specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol 1990; 145: 540–548
   PubMed Web of Science ®Google Scholar
• Pette M, Kyoko F, Wilkinson D, Altmann DM, Trowsdale J, Giegerich G, Hinkkanen A, Epplen JT, Kappos L H. Wekerle H. Myelin autoreactivity in multiple sclerosis: Recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and health donors. Proc Natl Acad Sci 1990; 87: 7968–7972
   PubMed Web of Science ®Google Scholar
• Martin R., Utz U, Coligan JE, Richert JR, Flerlage M, Robinson E, Stone R, Biddison WE, McFarlin DE, McFarland HF. Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J Immunol 1992; 148: 1359–1366
   PubMed Web of Science ®Google Scholar
• Pelfrey CM, Trotter JL, Rhame LB, McFarland HF. Identification of a novel T cell epitope of human proteolipid protein (residues 40-60) recognized by proliferative and cytolytic CD4+ cells form multiple sclerosis patients. J Neuroimmunol, In press
   Google Scholar
• Chou YK, Bourdette DN, Offner H, Whitham R, Wang R-Y, Hashim GA, Vandenbark AA. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. J Neuroimmunol 1992; 38: 105–111
   PubMed Web of Science ®Google Scholar
• McCarron RM, Fallis FJ, McFalin DE. Alterations in T cell antigen specificity and class II restriction during the course of chronic relapsing experimental allergic encephalomyelitis. J Neuroimmunol 1990; 29: 73–79
   PubMed Web of Science ®Google Scholar
• Scheherazade S-N, Germain RN. A role for peptide in determining MHC class II structure. Nature 1991; 353: 167–170
   Google Scholar
• Germain RN, Hendrix LR. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. Nature 1991; 353: 134–139
   Google Scholar
• Lakey EK, Casten LA, Niebling WL, Margoliash E, Pierce SK. Time dependence of B cell processing and presentation of peptide and native protein antigens. J Immunol 1988; 140: 3309–3314
   PubMed Web of Science ®Google Scholar
• Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 1992; 360: 474–477
   PubMed Web of Science ®Google Scholar
• Sette A, Ceman S, Kubo TR, Sakagushi K, Appella E, Hunt DF, Davis TA, Michel H, Shabanowitz J, Rudersdorf R, Grey HM, DeMar R. Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant. Science 1992; 258: 1801–1804
   PubMed Web of Science ®Google Scholar
• Cotner T, Mellins E, Johnson AH, Pious D. Mutations affecting antigen processing impair class II-restricted allo-recognition. J Immunol 1991; 146: 414–417
   Google Scholar
• Cotner T. Unassembled HLA-DR 0 monomers are degraded rapidly by a nonlysosomal mechanism. J Immunol 1992; 148: 2163–2168
   Google Scholar
• Harris PE, Liu Z, Suciu-Foca N. MHC class II binding of peptides derived from HLA-DR 1. J Immunol 1992; 148: 2169–2174
   Google Scholar
• Norton SD, Zuckerman L, Urdahl KB, Shefner R, Miller J, Jenkins MK. The CD28 Iigand, B7, enhances IL-2 production by providing a costimulatory signal to T cells. J Immunol 1992; 149: 1556–1561
   PubMed Web of Science ®Google Scholar
• Bal V, McLndoe A, Denton G, Hudson D, Lombardi G, Lamb J, Lechler R. Antigen presentation by keratinocytes induces tolerance in human T cells. Eur J Immunol 1990; 20: 1893–1897
   PubMed Web of Science ®Google Scholar
• Eynon EE, Parker DC. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med 1992; 175: 131–138
   PubMed Web of Science ®Google Scholar
• Celis E, Saibara T. Binding of T cell receptor to major histocompatibility complex class II-peptide complexes at the single-cell level results in the induction of antigen unresponsiveness (anergy). Eur J Immunol 1992; 22: 3127–3134
   Google Scholar
• Smilek DE, Wraith DC, Hodgkinson S, Dwivedy S, Steinman L, McDevitt HO. A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Proc Natl Acad Sci 1991; 88: 9633–9637
   PubMed Web of Science ®Google Scholar
• Gammon G, Sercarz E. How some T-cells escape tolerance induction. Nature 1989; 342: 183–185
   PubMedGoogle Scholar
• Ottenhoff TH, Mutis T. Specific killing of cytotoxic T cells and antigen-presenting cells by CD4+ cytotoxic T cell clones. A novel potentially immunoregulatory T-T cell interaction in man. J Exp Med 1990; 171: 2011–2024
   Google Scholar
• Su X-m, Sriram S. Treatment of chronic relapsing experimental allergic encephalomyelitis with the intravenous administration of splenocytes coupled to encephalitogenic peptide 91-103 of myelin basic protein. J Neuroimmunology 1991; 34: 181–190
   PubMed Web of Science ®Google Scholar
• Miller A, Lider O, Weiner JL. Antigen-driven bystander suppression after oral administration of antigens. J Exp Med 1991; 174: 791–798
   PubMed Web of Science ®Google Scholar
• Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor 0 after antigen-specific triggering. Proc Natl Acad Sci 1992; 89: 421–425
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci 1991; 88: 10252–10256
   PubMed Web of Science ®Google Scholar
• Karpus WJ, Gould KE, Swanborg RH. CD4+ suppressor cells of autoimmune encephalomyelitis respond to T cell receptor-associated determinants on effector cells by interleukin-4 secretion. Eur J Immunol 1992; 22: 1757–1763
   PubMed Web of Science ®Google Scholar
• Collins DS, Unanue ER, Harding CV. Reduction of disulfide bonds within lysosomes is a key step in antigen processing. J Immunol 1991; 147: 4054–4059
   PubMed Web of Science ®Google Scholar
• Jensen PE. Reduction of disulfide bonds during antigen processing: Evidence from a thiol-dependent insulin determinant. J Exp Med 1991; 174: 1121–1130
   Google Scholar
• Muller S, Plaue's S, Samama JP, Valette M, Briand JP, Van Regenmortel MH. Antigenic properties and protective capacity of a cyclic peptide corresponding to site A of influenza virus haemagglutinin. Vaccine 1990; 8: 308–314
   PubMed Web of Science ®Google Scholar